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This single-arm, open-label, phase II study in 42 Japanese postmenopausal patients
with estrogen receptor-positive/human epidermal growth factor receptor 2-nega-
tive (ER+/HER2) advanced breast cancer evaluated the efficacy, safety, and phar-
macokinetics of first-line palbociclib (125 mg once daily, 3 weeks on/1 week off)
coadministered with letrozole (2.5 mg once daily). Primary endpoint of investiga-
tor-assessed 1-year progression-free survival (PFS) probability was 75.0% (90% CI,
61.3%-84.4%), far surpassing the 40% lower limit of the 90% CI supporting effi-
cacy. Median duration of treatment was 438 days. Among secondary efficacy mea-
sures, median PFS was not reached (95% CI, 16.7: not estimable), 17/42 patients
(40.5%) had an objective response, 36/42 (85.7%) maintained disease control, and
27/42 (64.3%) remained in follow-up. Median overall survival was not reached,
and 1-year survival probability was 92.9% (95% CI, 79.5%-97.6%). Results of
intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady-
state mean area under the plasma concentration-time curve over the dosing inter-
val [s] and mean maximum plasma concentration were 1979 ngh/mL and
124.7 ng/mL, respectively. For day 15 plasma samples from cycles 1 and 2, geo-
metric mean of the within-patient mean trough concentration was 90.1 ng/mL.
The most common treatment-related adverse events were neutropenia (100%) and
stomatitis (73.8%). There was 1 case of treatment-related febrile neutropenia. Tox-
icities were generally tolerated and manageable by dose modifications and/or
medical care. Efficacy and safety of first-line palbociclib plus letrozole therapy is
supported in Japanese postmenopausal patients with treatment-naive ER+/HER2
advanced breast cancer.
Abbreviations: ABC, advanced breast cancer; AE, adverse event; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; AUCs, area under the
plasma concentration-time curve over dosing interval [s]; CDK4/6, cyclin-dependent kinases 4 and 6; CI, confidence interval; CL/F, apparent clearance; Cmax, maximum plasma concentration;
CR, complete response; Ctrough, trough concentration; CV, coefficient of variation; DCR, disease control rate; DOR, duration of response; ECG, electrocardiogram; ECOG PS, Eastern
Cooperative Oncology Group performance status; ER+, estrogen receptor-positive; FAS, full analysis set; HER2-, human epidermal growth factor receptor 2-negative; HPLC, high-performance
liquid chromatography; HR, hazard ratio; HR+, hormone receptor-positive; mBC, metastatic breast cancer; MedDRA, Medical Dictionary for Regulatory Activities; NE, not estimable; ORR,
objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PK, pharmacokinetics; PR, partial response; QD, once daily; QTc, corrected QT; RECIST,
Response Evaluation Criteria in Solid Tumors; tmax, time to Cmax; %CV, percentage coefficient of variation.
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1 | INTRODUCTION
The incidence of breast cancer in Japanese women increased 46%
from 1995 to 2015,1 and it is now the most common cancer and the
fifth leading cause of cancer-related deaths among Japanese
women.2 Globally, between 5% and 10% of breast cancers are meta-
static at the time of diagnosis,3 and ABC, including recurrent disease
and mBC, is incurable,4 posing a significant public health burden and
considerable treatment challenges.5
For postmenopausal women with HR+ ABC, endocrine therapy
with agents such as aromatase inhibitors (eg, anastrozole, letrozole,
or exemestane) is the standard first-line treatment6 and is recom-
mended by the Japanese Breast Cancer Society treatment guide-
lines.7 However, current first-line endocrine therapy alone may
provide only modest benefit in patients with HR+ ABC, and some
patients may not respond at all,6 indicating the need for new treat-
ment options. In a randomized phase III trial of exemestane vs anas-
trozole as first-line therapy in Japanese women with HR+ ABC,
median time to progression was approximately 12 months in each
group.8 Thus, there is interest in improving outcomes by combining
first-line endocrine therapy with other agents.
Palbociclib is a potent, orally active, highly selective inhibitor of
CDK4/6; it actively arrests cell cycle progression from the G1 phase
to the S phase to inhibit DNA synthesis and the pathologic cellular
proliferation characteristic of breast malignancies.9-11 Palbociclib
showed antiproliferative activity alone and synergistic activity with
tamoxifen in ER+ luminal breast cancer cell lines.10 In clinical trials in
non-Japanese patients with retinoblastoma protein-positive solid
tumors, single-agent palbociclib showed antitumor efficacy with an
acceptable safety profile and was well tolerated.12,13 In an open-
label, phase II PALOMA-1 trial, efficacy and safety of first-line letro-
zole (2.5 mg QD) alone or in combination with palbociclib (125 mg
QD, 3 weeks on, 1 week off [3/1 schedule]) was investigated in
non-Japanese postmenopausal women with ER+ and HER2 ABC.14
Median PFS was significantly longer with combination therapy than
with letrozole alone (20.2 vs 10.2 months, respectively; HR, 0.49;
95% CI, 0.32-0.75; one-sided P = .0004). AEs with combination ther-
apy were predictable and manageable; neutropenia was the most
commonly reported AE.14 These findings were confirmed in the
phase III PALOMA-2 trial in postmenopausal women with ER+/
HER2 ABC who received letrozole with or without palbociclib (3/1
schedule) as first-line therapy.15 Consistent with PALOMA-1, median
PFS was significantly longer with combination therapy than with
letrozole monotherapy (24.8 vs 14.5 months; HR, 0.58; 95% CI,
0.46-0.72; two-sided P < .001). AEs were similar to those reported
in the PALOMA-1 trial, with uncomplicated neutropenia being the
most commonly reported toxicity.15 Based on these findings, palbo-
ciclib was approved in the USA and Europe for the treatment of
HR+/HER2 mBC or ABC in combination with an aromatase inhibi-
tor as initial endocrine-based therapy.16,17
To investigate the efficacy, PK, and safety of palbociclib plus letro-
zole in Japanese patients, a phase I/II study was conducted in post-
menopausal Japanese women with ER+/HER2 ABC.18 In part 1 of
the phase I dose-finding study, single-agent palbociclib was given to
patients with advanced solid tumors that were refractory to standard
therapy. Maximum tolerated dose of palbociclib was 125 mg, and
safety findings were consistent with previous studies.18 In part 2, pal-
bociclib plus letrozole (same dosage regimen as in PALOMA-1 and
PALOMA-2 trials) was assessed as first-line therapy in post-
menopausal Japanese patients with ER+/HER2 ABC. There was no
evidence of a drug-drug interaction between palbociclib and letrozole;
thus, the recommended palbociclib dosage in Japanese patients is
125 mg QD (3/1 schedule) in combination with letrozole 2.5 mg
daily,18 the same dosing regimen used to treat Western patients.
The PALOMA-1 trial did not include Japanese patients, and the
results of the PALOMA-2 trial were not available when this study
started. Thus, the primary objective of the phase II portion of this
phase I/II study was to evaluate the efficacy of palbociclib in combi-
nation with letrozole using 1-year PFS probability in postmenopausal
Japanese patients with ER+/HER2 ABC.
2 | MATERIALS AND METHODS
2.1 | Study design
This was the phase II portion of a phase I/II, single-country, non-ran-
domized, open-label, single-arm, multicenter study in Japanese
patients (NCT01684215). The phase I part of this study has been
published.18 The primary objective of the phase II part of the study
was to evaluate the efficacy of palbociclib in combination with letro-
zole using 1-year PFS probability in postmenopausal Japanese
patients with ER+/HER2 ABC. There were several secondary
objectives. We assessed ORR, DCR, DOR, PFS, 1-year survival, and
OS. Additional assessments included safety and tolerability, evalua-
tion of health-related quality of life (not reported), determination of
plasma Ctrough of palbociclib combined with letrozole in all patients,
and evaluation of the full PK profile of palbociclib in a subset of
treated patients (n = 6). We also characterized biomarkers of tumor
sensitivity and/or resistance in tumor tissue samples, such as the Ki-
67 index, for which a 20% cutoff has been determined to be optimal
(a significant factor for overall survival), or the most effective prog-
nostic factor for luminal/HER2 breast cancer based on a study of
4329 Japanese patients with primary breast cancer.19
The study protocol was approved by the Institutional Review
Board at each participating center, and written informed consent
was obtained from all patients before enrollment. The study was
804 | MASUDA ET AL.
conducted according to applicable local laws and regulatory require-
ments, the International Conference on Harmonisation Good Clinical
Practice guidelines, and the Declaration of Helsinki.
2.2 | Patients
Key inclusion criteria included Japanese postmenopausal women
(≥20 years of age) with histologically or cytologically confirmed ER+
ABC (locoregionally recurrent or metastatic disease not suitable for
resection or radiation therapy with curative intent) who had received
no prior systemic anticancer therapy for ER+ ABC, and who had
measurable disease (per RECIST, version 1.120) or bone-only disease,
ECOG PS 0-2, and adequate bone marrow, renal, and liver function.
Key exclusion criteria were a HER2+ tumor identified by proto-
col-specified diagnostics; advanced, symptomatic, visceral spread;
and risk of life-threating complications, known active uncontrolled or
symptomatic central nervous system metastases, carcinomatous
meningitis, or leptomeningeal disease. Patients who had received
prior (neo)adjuvant treatment with a non-steroidal aromatase inhibi-
tor and had disease recurrence during treatment or ≤12 months
after completing treatment, or prior treatment with CDK4/6 inhibi-
tors were also excluded. Patients with baseline QTc >480 ms (based
on the mean value of triplicate ECGs), family or personal history of
QT syndrome were also ineligible.
2.3 | Study treatment
Patients received 125 mg palbociclib orally QD with food on days 1
to 21 of every 28-day cycle followed by 7 days off palbociclib treat-
ment, coadministered with letrozole 2.5 mg orally QD. Study treat-
ments were continued until radiologically documented PD according
to RECIST (v1.1), symptomatic deterioration, unacceptable toxicity,
or withdrawal of consent.
Palbociclib dose interruptions or delays were permitted if patients
experienced the following protocol-specified treatment-related AEs:
uncomplicated grade 3 neutropenia (ANC <1000/mm3), grade 3 neu-
tropenia associated with a documented infection or fever ≥38.5°C,
grade 4 neutropenia (ANC <500/mm3), grade 4 thrombocytopenia
(platelet count <25 000/mm3), grade ≥3 non-hematologic toxicity, or
grade 3 QTc prolongation (QTc ≥501 ms on ≥2 separate ECGs).
Retreatment after dose interruption for treatment-related toxicity or
at the start of a new cycle was permitted when all of the following cri-
teria were met: platelet count ≥50 000/mm3, ANC ≥1000/mm3 with-
out fever, grade ≥3 treatment-related non-hematologic AE that had
recovered to grade ≤1 or baseline (or at the investigator’s discretion or
if grade ≤2 AEs were not considered a safety risk), QTc <501 ms and
potential reversible causes (eg, electrolyte imbalance, concomitant
medications known to prolong QTc) were corrected. If QTc remained
>480 ms, more frequent ECG monitoring occurred per the investiga-
tor’s best medical judgment until QTc was ≤480 ms. If these criteria
were met within 2 weeks of the dose interruption or cycle delay, pal-
bociclib treatment was resumed. If not, resumption or permanent dis-
continuation of palbociclib treatment was based on the investigator’s
best medical judgment of whether the patient was deriving clinical
benefit from treatment.
Protocol-specified palbociclib dose reductions were permitted,
depending on the type and severity of toxicity reported. The recom-
mended first dose reduction was from 125 to 100 mg/d, and the
recommended second dose reduction was from 100 to 75 mg/d.
Patients requiring >2 palbociclib dose reductions were discontinued
from the study but remained in the follow-up phase. Subsequent
treatment cycles were given at the reduced dose level; dose re-esca-
lation was not permitted. Patients who continued receiving letrozole
remained in the active treatment phase of the study.
Letrozole dose interruptions for treatment-related toxicities were
permitted based on the investigator’s judgment. Letrozole dose
reductions were not permitted. Patients who discontinued letrozole
because of treatment-related toxicity also discontinued palbociclib
and, consequently, were discontinued from the active treatment
phase of the study and instead entered the follow-up phase.
2.4 | Assessments
2.4.1 | Efficacy
Disease assessments included computed tomography or magnetic res-
onance imaging of the chest, abdomen, pelvis, and any other sites of
disease as clinically indicated; clinical assessment of superficial disease
(including lesion measurements); and radionucleotide bone scans. All
baseline assessments were carried out before giving study drugs (pal-
bociclib and letrozole). Postbaseline tumor assessments were done
every 12 weeks and bone scans (if applicable) every 24 weeks until
evidence of disease progression. Radiographic disease progression
using RECIST or clinical disease progression (if photographed or palpa-
ble lesions) was assessed. Objective tumor response (using RECIST)
was reported as ORR (percentage of patients with CR + PR) and DCR
(percentage of patients with CR + PR + stable disease lasting
≥24 weeks). All radiographic or clinical (where applicable) efficacy
evaluations were based on investigator assessments. OS was deter-
mined every 6 months from the last dose of study treatment.
2.4.2 | Pharmacokinetics
A subset of 6 patients underwent intensive PK sampling, and blood
samples were taken on cycle 1/day 15 at predose and at 1, 2, 4, 6,
8, 10, and 24 hours after dosing, then at predose on cycle 2/day 15.
For this subset, plasma concentration-time data obtained after study
drug administration on cycle 1/day 15 were analyzed using non-
compartmental analysis methods to determine the following PK
parameters: Cmax, tmax, AUCs, and CL/F. For assessment of palboci-
clib plasma Ctrough, blood samples from all patients were collected on
day 15 of cycles 1 and 2 before giving study drug. Plasma samples
were analyzed for palbociclib concentrations using a validated HPLC
method with tandem mass spectrometry at PPD Development (Rich-
mond, VA, USA). Lower limit of quantification for palbociclib was
1.00 ng/mL.
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2.4.3 | Safety
Safety was assessed by treatment-related AEs and clinically signifi-
cant changes in physical examination findings or abnormal laboratory
assessments. AEs were reported throughout the study using Med-
DRA version 18.1 (International Council for Harmonisation, Geneva,
Switzerland), and protocol-specified clusters of preferred terms,
based on incidence, severity (using Common Terminology Criteria for
Adverse Events, version 4.0), and investigator-assessed relationship
to study treatment. Physical examinations and 12-lead ECGs were
carried out at baseline, day 1 of each cycle, and at the end of treat-
ment. Laboratory assessments (hematology and blood chemistry)
were conducted at baseline, days 1 and 15 of cycle 1, and on day 1
of each subsequent cycle.
2.5 | Statistical analyses
Primary endpoint of this study was the 1-year PFS probability of the
lower limit of the 90% CI exceeding 40%, which would correspond
to a median PFS of 9 months, assuming that PFS had an exponential
distribution. Sample size for this study was 32 patients to meet the
above criteria with a >80% probability based on the assumption that
median PFS for patients receiving palbociclib plus letrozole was
18 months. Accounting for a 20% potential patient drop-out, total
enrollment target was 40 patients.
The FAS, defined as all patients who received ≥1 dose of palbociclib,
was used for all efficacy analyses. Primary endpoint of 1-year PFS was
defined as the proportion of patients without PFS events (ie, PD or
death from any cause) at 12 months after the first palbociclib dose. PFS
and 90% CI were estimated using the Kaplan-Meier method.
Subgroup analyses of PFS were carried out to investigate the
effects of baseline disease characteristics (ie, visceral vs non-visceral
metastases, length of disease-free interval since completion of prior
treatment [≤12 months vs >12 months vs de novo metastatic dis-
ease]). Exploratory analysis of the association between baseline Ki-
67 status (ie, Ki-67-positive cells ≤20% vs >20%, central laboratory
assessed) and PFS was also conducted. All subgroup analyses of
PFS, median PFS, and 95% CI were estimated using the Kaplan-
Meier method.
Objective response rate and DCR were estimated. DOR was
based on the subset of patients in the FAS who had an objective
response (CR or PR) and was defined as the time from first objective
response to first objective PD or death. OS was estimated using the
Kaplan-Meier method, and 1-year OS was calculated in the same
way as for 1-year PFS.
The PK analysis set was defined as all patients with ≥1 PK
parameter of primary interest in ≥1 PK sampling period. PK parame-
ters are presented using descriptive statistics. For the full palbociclib
PK profile subset (n = 6), plasma concentration-time data obtained
after giving palbociclib on cycle 1/day 15 were also summarized
descriptively and are presented graphically. Steady-state palbociclib
Ctrough values for all patients were calculated as geometric mean and
geometric %CV.
The study is still ongoing for the collection of survival data.
3 | RESULTS
3.1 | Patient disposition
Forty-three patients were enrolled at 16 centers in Japan, and
patient accrual for this study was conducted between June 24, 2014
and February 9, 2015. Of the 43 enrolled patients, 42 were treated
with palbociclib plus letrozole and included in the efficacy analyses.
The enrolled but untreated patient became ineligible for treatment
after an early unplanned examination showed the presence of
another malignancy. At the time of data cutoff (March 4, 2016), 27
of 42 patients (64.3%) were continuing their treatment, and 15 of
42 (35.7%) had discontinued the study treatment. The most common
reason for discontinuing treatment was objective disease progression
or relapse (n = 10 for both palbociclib and letrozole). Four patients
discontinued the study (2 of 3 patients died as a result of underlying
disease and 1 patient refused further follow up after objective pro-
gression or relapse, her last dose of palbociclib was on day 42). The
remaining 38 patients in the study were ongoing at the data cutoff.
Baseline demographics and clinical characteristics of patients in
the FAS are shown in Table 1. Median age of women was
62.5 years (range, 43-84 years), and median weight was 50.4 kg
(range, 38.6-74.5 kg; Table 1). Twelve patients (28.6%) had Stage IV
disease at study entry. At baseline, most patients (93%) had an
ECOG PS of 0, 20 patients (47.6%) had visceral disease, and many
(28 patients, 66.7%) had received ≥1 prior (neo)adjuvant systemic
therapies, including 20 patients (47.6%) who had prior chemother-
apy.
3.2 | Efficacy
At the March 4, 2016 data cutoff, 1-year PFS probability was 75.0%
(90% CI, 61.3%-84.4%). Of the 42 patients in the FAS, 12 (28.6%)
had PFS events and most events (11/12) were associated with
objective disease progression. Median PFS was not reached (95% CI,
16.7 months: NE; Figure 1A). At the October 31, 2016 data cutoff,
the updated 1-year PFS probability was 75.6% (90% CI, 62.4%-
84.7%). Median PFS was still immature (not reached [95% CI,
21.7 months: NE]; Figure 1B).
Subgroup analyses of PFS by specific baseline characteristics and
treatment characteristics are shown in Figure 2. For patients with
visceral vs non-visceral metastases at baseline, 1-year PFS probabil-
ity was 51.8% (90% CI, 31.0%-69.2%) and 95.2% (77.7%-99.1%),
respectively. Median PFS was 16.7 months (95% CI, 5.3–NE) in
patients with visceral metastases and was not reached in patients
with non-visceral metastases (Figure 2A). One-year PFS probability
by patient’s disease-free interval at baseline from completion of prior
therapy (≤12 months vs >12 months vs de novo metastatic disease)
was 60.0% (90% CI, 25.8%-82.5%), 79.3% (58.9%-90.4%), and 78.6%
(53.5%-91.1%), respectively. Median PFS was not reached in any of
these subgroups (Figure 2B).
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In patients with tumor biopsies expressing Ki-67-positive cells
≤20% vs >20%, median PFS was not reached in the former and was
reached at 16.7 months (95% CI, 9.3–NE) in the latter (Figure 2C).
Median PFS was not reached in patients who had a dose reduction
and was 16.7 months (95% CI, 8.1–NE) in patients who did not have
a dose reduction (Figure 2D).
The ORR was 40.5% (95% CI, 25.6%-56.7%) and the DCR was
85.7% (95% CI: 71.5%-94.6%); no patient had achieved a CR. In the
response evaluable analysis set, which was in patients with measur-
able disease, ORR was 47.2% (95% CI, 30.4%-64.5%) and DCR was
83.3% (95% CI, 67.2%-93.6%). Median DOR was not reached (95%
CI, 6.5 months–NE). Only 3 OS events (7.1%) had occurred, and
median OS was not reached. Most patients (90.5%) were still in fol-
low up for OS at the data cutoff. Survival probability at 12 months
was 92.9% (95% CI, 79.5%-97.6%).
3.3 | Pharmacokinetics
For the PK analyses, data cutoff was September 25, 2015. Palboci-
clib steady-state mean AUCs and Cmax were 1979 ngh/mL and
124.7 ng/mL, respectively, for the subset of patients who underwent
intensive PK sampling (n = 6; Table 2). Interpatient variability (geo-
metric %CV) of palbociclib steady-state AUCs (ngh/mL) and Cmax
(ng/mL) were 16% and 26%, respectively. Median palbociclib steady-
state concentration-time profile on cycle 1/day 15, when coadminis-
tered with letrozole, is shown in Figure 3 (n = 6).
Mean palbociclib Ctrough in combination with letrozole on cycle
1/day 15 and cycle 2/day 15 were determined for all patients in the
PK population (n = 38; Table 3). Mean Ctrough values on each
TABLE 1 Baseline demographics and disease characteristics of




Median age (range), y 62.5 (43-84)
Median weight (range), kg 50.4 (38.6-74.5)
ECOG performance status, n (%)
0 39 (92.9)
1 3 (7.1)
Disease site (visceral involvement), n (%)a
Visceral 20 (47.6)
Non-visceral 22 (52.4)
Disease site (bone involvement), n (%)
Bone only 6 (14.3)
Other with measurable disease 36 (85.7)
Disease site, n (%)b
Bone 24 (57.1)
Breast 17 (40.5)
Pleural effusion 4 (9.5)
Lung 14 (33.3)
Pleura 4 (9.5)
Lymph node 23 (54.8)
Liver 5 (11.9)
Other 7 (16.7)







Disease-free interval, n (%)c
≤12 mo 8 (19.0)
>12 mo 20 (47.6)
De novo metastatic disease 14 (33.3)


















Prior therapies for primary diagnosis, yes, n (%)
Prior surgery 30 (71.4)
Prior radiation therapy 19 (45.2)
Prior systemic therapye 28 (66.7)
Chemotherapy 20 (47.6)
Endocrine 27 (64.3)
ABC, advanced breast cancer; ECOG, Eastern Cooperative Oncology
Group; ER+, estrogen receptor-positive; HER2, human epidermal
growth factor receptor 2-negative.
aVisceral refers to lung (including pleura) and/or liver involvement.
bInvolved sites include both target and non-target sites. Sites with multi-
ple lesions were counted once. Patients may have contributed to >1 cat-
egory.
cDisease-free interval was calculated as the time between end of neoad-
juvant or adjuvant treatment and onset of metastatic disease or disease
recurrence.
dTumor tissue samples were from metastatic/recurrent tumor lesions
whenever possible; when unavailable, a de novo fresh biopsy was recom-
mended if judged by the investigator to be feasible and safe. Original
diagnostic tissue was also collected when available.
eNeoadjuvant or adjuvant therapy.
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sampling day overlapped (89.4 ng/mL in cycle 1 and 86.8 ng/mL in
cycle 2), and the geometric mean Ctrough obtained from day 15 of
cycles 1 and 2 at steady state was 90.1 ng/mL.
3.4 | Safety
3.4.1 | Exposure
Median duration of treatment was 438.0 days (range: 56-585), and
patients received a median of 14 (range, 2-21) treatment cycles as
of data cutoff date of March 4, 2016 (Table 4). Median relative dose
intensity was 74.2% for palbociclib and 99.7% for letrozole. In total,
25 patients (59.5%) required ≥1 palbociclib dose reduction. Letrozole
dose reductions were not permitted, but dosing interruptions for
letrozole-related toxicities were allowed per the investigator’s best
medical judgment. Dose modifications (dose reductions, dose inter-
ruptions, and cycle delays) are also summarized in Table 4.
3.4.2 | Treatment-related adverse events
The most common treatment-related AEs (by clustered preferred
term) were neutropenia (100% of patients), stomatitis (73.8%), and
leukopenia (71.4%), and the most common treatment-related grade 3
or 4 AEs were neutropenia (90.5%), and leukopenia (50.0%; Table 5).
There was 1 case of treatment-related grade 3 febrile neutropenia
(onset day 18) that resolved by day 29.
3.4.3 | Serious adverse events and deaths
Serious AEs were reported in 3 patients (7.1%) and included vomit-
ing, malaise, dizziness, and subarachnoid hemorrhage (in 1 patient),
febrile neutropenia (1 patient), and cerebral hemorrhage (1 patient).
Two of these events were considered treatment-related (subarach-
noid hemorrhage and febrile neutropenia). The patient who experi-
enced the treatment-related subarachnoid hemorrhage died; the last
doses of palbociclib and letrozole were given 12 and 5 days, respec-
tively, before death.
Treatment-related AEs leading to permanent discontinuation of
treatment were reported in 3 patients (7.1%) who permanently dis-
continued palbociclib only (neutropenia in each patient) and in 3
patients (7.1%) who discontinued both palbociclib and letrozole
(malaise, ALT and AST increased, and subarachnoid hemorrhage in 1
patient each; Table S1). Treatment-related AEs leading to dose
reductions were reported in 25 patients (59.5%); the most common
reason was neutropenia (20 patients [47.6%]).
No patients had a QTc interval of ≥500 ms, and there were no
clinically relevant changes in vital signs during the study.
4 | DISCUSSION
In this open-label, phase II study in postmenopausal Japanese
women with ER+/HER2 ABC, first-line treatment with the combi-
nation of palbociclib 125 mg daily (3/1 schedule) plus letrozole
2.5 mg daily resulted in a 1-year PFS probability of 75.0% (90% CI,
61.3%-84.4%) at the time of the initial March 4, 2016 data cutoff.
Thus, the expected efficacy of palbociclib plus letrozole was
observed because the lower limit of the 90% CI exceeded 40%. At
the later October 31, 2016 data cutoff, 1-year PFS probability was
75.6% (90% CI, 62.4%-84.7%). The 1-year PFS probability in this
study was similar to the results in the PALOMA-1 and PALOMA-2
studies.21 Median PFS in patients in the PALOMA-1 study was
20.2 months (95% CI, 13.8-27.5) and in the PALOMA-2 trial it was
24.8 months (22.1–NE) after a median follow up of 29.6 and
23 months, respectively.14,15 The median PFS was not reached by
the primary cutoff date (March 4, 2016) or the extended cutoff date
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Palbociclib + letrozole 42 41 35 33 29 28 19 027 9
13 (21.7–NE)
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F IGURE 1 Investigator-assessed progression-free survival in
Japanese postmenopausal women with estrogen receptor-positive/
human epidermal growth factor receptor 2-negative advanced breast
cancer receiving palbociclib plus letrozole (N = 42) at the (A) March
4, 2016 data cutoff and (B) October 31, 2016 data cutoff. mPFS,
median progression-free survival; NE, not estimable; NR, not
reached
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reached 16.7 and 21.7 months at the respective cutoff dates. Effi-
cacy data for this study after a longer duration of follow up will be
further evaluated.
In the current study, subgroup analyses provided valuable
insights into the effects of baseline characteristics and study treat-
ment characteristics on PFS. One-year PFS probability was higher in
patients with non-visceral vs visceral metastases, in patients with
de novo metastatic disease or a disease-free interval >12 months vs
≤12 months. For median PFS, the sample size may have precluded a
conclusive result for the subgroup analysis by disease-free interval.
A similar trend, suggesting that de novo metastatic disease or a
disease interval >12 months had a favorable effect, was observed in
a subgroup analyses of PALOMA-2 patients.22 In PALOMA-2, a sub-
group analysis suggested palbociclib plus letrozole improved PFS
regardless of baseline characteristics, including by disease sites or
disease-free interval.22 In this Japanese study, the Kaplan-Meier plot
was similar in patients who required a dose reduction on treatment
vs patients who did not, suggesting palbociclib dose reductions,
which were predominantly from 125 to 100 mg, appear not to affect
efficacy. Because these data are still immature, the impact of dose
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≤12 mo 8 3 NR (5.1–NE)
>12 mo 20 5 NR (16.7–NE)
de novo
metastatic 14 4 NR (4.5–NE)
* * * 
*  * * 
F IGURE 2 Investigator-assessed progression-free survival in Japanese postmenopausal women with estrogen receptor-positive/human
epidermal growth factor receptor 2-negative advanced breast cancer receiving palbociclib plus letrozole (N = 42). A, Visceral vs non-visceral
metastases at baseline. B, Disease-free interval (≤12 mo vs >12 mo from end of treatment vs de novo metastatic disease). C, Ki-67-positive
cells ≤20% vs >20% at baseline. D, Dose reduction vs no dose reduction (at the March 4, 2016 cutoff). mPFS, median progression-free
survival; NE, not estimable; NR, not reached
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In the subgroup analysis of Ki-67 positivity (a prognostic biomar-
ker for cell proliferation in breast cancer23), patients with ≤20% Ki-
67-positive cells at baseline had a prolonged median PFS compared
with those with >20% Ki-67-positive cells, supporting the prognostic
value of this biomarker in patients with breast cancer. In PALOMA-
2, Ki-67 index values at a 15% or 20% cutoff did not show a patient
group with a better or worse PFS with palbociclib plus letrozole.24
At the initial data cutoff, 40.5% of patients had an objective
response to treatment and the median DOR had not been reached.
These findings are comparable to the objective responses of 43%
and 42% in the PALOMA-1 and PALOMA-2 trials, respectively.
Moreover, the proportion of patients with disease control in the cur-
rent study (85.7%) was similar to those in PALOMA-1 (81%) and
PALOMA-2 (84.9%).14,15
In the current study, median OS also had not been reached by
March 4, 2016. The 1-year survival probability was 92.9%, with only
3 deaths reported, and with most patients remaining in the follow-
up phase at the time of data cutoff. Overall, the efficacy data from
the current phase II study in postmenopausal Japanese women with
ER+/HER ABC who received first-line palbociclib plus letrozole are
consistent with data from the 2 large PALOMA-1 and PALOMA-2
trials in non-Japanese patients, or predominantly non-Japanese
patients, respectively.14,15
When coadministered with letrozole, the full PK analysis con-
ducted in 6 Japanese patients in the current study showed a PK
profile that was remarkably similar to that reported in the
PALOMA-1 study in non-Japanese patients.25 The Ctrough of plasma
palbociclib in all patients was 89.4 and 86.8 ng/mL on day 15 of
cycles 1 and 2, respectively. These data are highly consistent with
the exploratory findings from the phase I portion of this study
when the plasma palbociclib Ctrough was 72.8 ng/mL after multiple
oral doses on day 8 of cycles 1 and 2 when coadministered with
letrozole.18 In the phase II portion of PALOMA-1, the Ctrough of
plasma palbociclib was 63.5 and 62.4 ng/mL on day 14 of cycles 1
and 2, respectively, collectively indicating that the plasma palboci-
clib mean Ctrough appeared to be slightly higher in Japanese
patients; however, the distribution of plasma Ctrough in this study
and PALOMA-1 overlap.
In the current study, palbociclib in combination with letrozole
was well tolerated. The most commonly reported AE was uncompli-
cated neutropenia, and AEs were manageable by implementing pal-
bociclib dose interruptions or reductions and/or standard medical
therapy. These findings are consistent with the known safety profile
TABLE 2 Plasma palbociclib steady-state pharmacokinetics in a
subset of 6 Japanese postmenopausal patients with ER+/HER2






AUCs (ngh/mL) 1979 (16)
Cmax (ng/mL) 124.7 (26)
tmax (h) 4.90 (2.00-8.20)
CL/F (L/h) 63.2 (16)
ABC, advanced breast cancer; AUCs, area under the plasma concentra-
tion-time curve over dosing interval s using the linear/log trapezoidal
method; CL/F, apparent clearance determined by dose/AUCs; Cmax, maxi-
mum plasma concentration observed directly from the data; ER+, estro-
gen receptor-positive; HER2, human epidermal growth factor receptor
2-negative; tmax, time to Cmax observed directly from the data as time of
first occurrence.
aData are geometric mean (geometric % coefficient of variation) except






























Nominal time postdose (h)
0 4 8 12 16 202 6 10 14 18 22 24
F IGURE 3 Mean plasma palbociclib steady-state concentration-
time profile in Japanese postmenopausal women with estrogen
receptor-positive/human epidermal growth factor receptor 2-
negative advanced breast cancer on cycle 1/day 15 following
palbociclib 125 mg daily oral doses plus letrozole 2.5 mg daily oral
doses (n = 6). Error bars represent  standard deviation
TABLE 3 Mean palbociclib plasma Ctrough in combination with














cycles 1 and 2b
N 32 30 38
Ctrough (ng/mL) 89.4 (44) 86.8 (40) 90.1 (42)
Ctrough, predose concentration during multiple dosing; N, number of
patients evaluated with the steady-state Ctrough.
The calculation required 2 conditions to be met for the steady state
Ctrough evaluable criteria: (i) Ctrough following at least 7 consecutive days
of palbociclib 125 mg daily dose without dosing interruption, and (ii)
Ctrough to have the actual sampling time, which was ≤10% time deviation
of the nominal time from 24 h after the last dose on day 14.
aGeometric mean (geometric % coefficient of variation) for all.
bGeometric mean of within-patient mean Ctrough on cycles 1 and 2 on
day 15.
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of palbociclib in non-Japanese patients with advanced ER+/HER2
breast cancer and other solid tumors12-15 and similar to the findings
from the phase I part of this study in Japanese patients.18
Limitations of the current study include the open-label and
single-arm design and the fact that all efficacy evaluations were
based on investigator assessments. However, the efficacy data are
consistent with those from other studies of this therapeutic combi-
nation.14,15 In addition, because the median duration of treatment
was only 438.0 days (range: 56-585) as of the data cutoff date of
TABLE 4 Exposure to study drugs and time and duration of dose
modifications in Japanese postmenopausal patients with ER+/










Median duration (range), d 438.0 (56-585)








≥1 dose reduction, n (%)b,c 25 (59.5) —
Patients with a dose
reduction to 100 mg
17 (40.5) —
Patients with a dose
reduction to 75 mg
8 (19.0) —
Median time to dose
reduction (range), dd
—
First dose reduction 64 (29-232)
Second dose reduction 114 (64-415)




5.5 (1.0-8.5) 1.0 (1.0-24.5)
Median time to first
dose interruption
(range), dd
15 (5-124) 107 (5-404)
Cycle delay, n (%) 39 (92.9) 8 (19.0)
Median average duration
of cycle delay, d (range)




74.2 (38.0-99.8) 99.7 (69.6-100)
ABC, advanced breast cancer; d, day; ER+, estrogen receptor-positive;
HER2, human epidermal growth factor receptor 2-negative.
aTotal number of dosing days (from the first day until and including the
last day) of each study treatment.
bAny dose reduction from the initial prescribed dose, regardless of dura-
tion (does not include dose interruptions).
cTotal number of patients categorized at the maximum dose reduction.
dTime to first event (dose reduction/dose interruption) = (start date of
first occurrence minus first dose date of cycle 1) + 1; for dose interrup-
tion, time could not be calculated for some patients as a result of
unknown dates for missing doses.
e0 mg given on a planned dosing day. Could not be calculated for some
patients as a result of unknown dates for missing doses.
fDuring total cycles.
gOverall relative dose intensity = (sum of overall cycles of actual total dose
per cycle/sum over all cycles of the actual number of weeks in cycle)/(sum
over all cycles of intended total dose per cycle/sum over all cycles of
intended number of weeks per cycle) 9 100. —, not applicable because a
dose reduction for letrozole was not allowed per the study protocol.
TABLE 5 Investigator-assessed treatment-related adverse events
of all grades and grades 3/4 occurring in ≥10% of patients (all
cycles) in Japanese postmenopausal patients with ER+/HER2 ABC





All grades Grade 3/4
Any AE, n (%) 42 (100)d 38 (90.5)
Hematologic AE
Neutropeniaa 42 (100) 38 (90.5)
Leukopeniaa 30 (71.4) 21 (50.0)
Thrombocytopeniaa 11 (26.2) 1 (2.4)
Anemia 8 (19.0) 2 (4.8)
Non-hematologic AE
Stomatitisa 31 (73.8) 0
Infectionsa 10 (23.8) 0
Constipation 9 (21.4) 0
Rasha 8 (19.0) 0
ALT increased 8 (19.0) 4 (9.5)
Alopecia 7 (16.7) NA
AST increased 7 (16.7) 1 (2.4)
Malaise 7 (16.7) NA
Headache 6 (14.3) 0
ABC, advanced breast cancer; AE, adverse event; ALT, alanine amino-
transferase; AST, aspartate aminotransferase; ER+, estrogen receptor-
positive; HER2, human epidermal growth factor receptor 2-negative;
MedDRA, Medical Dictionary for Regulatory Activities, version 18.1; NA,
grade 3 or 4 is not applicable.
aClustered preferred terms (PTs) were used to represent multiple PTs as
follows: Infections included any event with a PT that is part of the Med-
DRA system organ class “Infections and Infestations,” and in this study,
related PTs included angular cheilitis, cellulitis, gingivitis, laryngitis, lip
infection, nasopharyngitis, oral herpes, otitis media, pharyngitis, or upper
respiratory tract infection; Leukopenia included the PT leukopenia or
white blood cell count decreased; Neutropenia included the PT neu-
tropenia or neutrophil count decreased; Rash included the PT rash, rash
maculopapular, dermatitis, dermatitis or acneiform; Stomatitis included
the PT cheilitis, glossitis, oropharyngeal pain, or stomatitis; Thrombocy-
topenia included the PT thrombocytopenia or platelet count decreased.
bMedDRA.
cNational Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0 Grade ≤1 (except alopecia or other toxicities not con-
sidered a safety risk for the patient at investigator’s discretion).
dAmong all reported events, 1 (2.4%) patient had a grade 5 subarachnoid
hemorrhage.
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March 4, 2016, it was not possible to observe late AEs with palboci-
clib.
For decades, endocrine therapy has been the preferred first-line
treatment in patients with advanced ER+/HER2 breast cancer
because of its confirmed potential to prolong disease control, low
toxicity profile, and tolerability.26 Newer hormonal agents have
improved outcomes to some degree, but combination therapies of
hormonal agents with agents targeting other pathways may enhance
outcomes further in patients with advanced disease. This approach
has been successful in the second-line setting following prior endo-
crine resistance, where median PFS was shown to have not been
reached with a combination of palbociclib plus fulvestrant vs
5.8 months with placebo plus fulvestrant (HR, 0.49; 95% CI, 0.27-
0.87; P < .01) in premenopausal and postmenopausal Asian patients
(n = 72) with advanced ER+ breast cancer.27
In conclusion, first-line therapy with palbociclib plus letrozole
was effective and AEs were manageable in postmenopausal Japa-
nese women with advanced ER+/HER2 breast cancer. Palbociclib
in combination with letrozole should be considered as a first-line
treatment option in Japanese patients in this population.
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